| Variable . | Total cohort, No. (%) . | Low riskb, No. (%) . | High riskb, No. (%) . | Pc . |
|---|---|---|---|---|
| Sex | .003 | |||
| Male | 2200 (53.5) | 590 (57.4) | 1610 (52.2) | |
| Female | 1914 (46.5) | 437 (42.6) | 1477 (47.8) | |
| Age at diagnosis, y | .003 | |||
| 66-70 | 612 (14.9) | 184 (17.9) | 428 (13.9) | |
| 71-75 | 920 (22.4) | 243 (23.7) | 677 (21.9) | |
| 76-80 | 956 (23.2) | 230 (22.4) | 726 (23.5) | |
| >80 | 1626 (39.5) | 370 (36.0) | 1256 (40.7) | |
| Race | .13 | |||
| Black | 128 (3.1) | 29 (2.8) | 99 (3.2) | |
| Hispanic | 56 (1.4) | 11 (1.1) | 45 (1.5) | |
| White | 3702 (90.0) | 943 (91.8) | 2759 (89.3) | |
| Other | 228 (5.5) | 44 (4.3) | 184 (6.0) | |
| Marital status | .80 | |||
| Single | 497 (12.1) | 121 (11.8) | 376 (12.2) | |
| Married | 2331 (56.6) | 591 (57.5) | 1740 (56.4) | |
| Unknown | 1286 (31.3) | 315 (30.7) | 971 (31.5) | |
| Census region | .01 | |||
| West | 1615 (39.3) | 364 (35.4) | 1251 (40.5) | |
| Midwest | 929 (22.6) | 264 (25.7) | 665 (21.5) | |
| South | 487 (11.8) | 125 (12.2) | 362 (11.7) | |
| Northeast | 1083 (26.3) | 274 (26.7) | 809 (26.2) | |
| Median income | .50 | |||
| Bottom quartile | 1095 (26.6) | 286 (27.8) | 809 (26.4) | |
| Second quartile | 1033 (25.1) | 263 (25.6) | 770 (24.9) | |
| Third quartile | 1003 (24.4) | 234 (22.8) | 769 (24.9) | |
| Fourth quartile | 983 (23.9) | 244 (23.8) | 739 (23.9) | |
| No. of comorbidities | .12 | |||
| 0 | 1817 (44.2) | 429 (41.7) | 1388 (45.0) | |
| 1 | 1023 (24.9) | 268 (26.1) | 755 (24.4) | |
| 2 | 597 (14.5) | 167 (16.3) | 430 (13.9) | |
| ≥3 | 677 (16.5) | 163 (15.9) | 514 (16.7) | |
| Year of diagnosis | .55 | |||
| 2004 | 458 (11.1) | 115 (11.2) | 343 (11.1) | |
| 2005 | 424 (10.3) | 115 (11.2) | 309 (10.0) | |
| 2006 | 405 (9.8) | 82 (8.0) | 323 (10.5) | |
| 2007 | 415 (10.1) | 107 (10.4) | 308 (10.0) | |
| 2008 | 455 (11.1) | 117 (11.4) | 338 (10.9) | |
| 2009 | 446 (10.8) | 119 (11.6) | 327 (10.6) | |
| 2010 | 382 (9.3) | 89 (8.7) | 293 (9.5) | |
| 2011 | 389 (9.5) | 100 (9.7) | 289 (9.4) | |
| 2012 | 364 (8.8) | 87 (8.5) | 277 (9.0) | |
| 2013 | 376 (9.1) | 96 (9.3) | 280 (9.1) | |
| Grade | <.001 | |||
| Low | 1318 (32.0) | 1027 (100) | 291 (9.4) | |
| High | 2556 (62.2) | 0 (0) | 2556 (82.8) | |
| Unknown | 240 (5.8) | 0 (0) | 240 (7.8) | |
| AJCC T stage | <.001 | |||
| Ta | 998 (24.3) | 680 (66.2) | 318 (10.3) | |
| T1 | 921 (22.4) | 347 (33.8) | 574 (18.6) | |
| T2 | 557 (13.5) | 0 (0) | 557 (18.0) | |
| T3 | 1136 (27.6) | 0 (0) | 1136 (36.8) | |
| T4 | 266 (6.5) | 0 (0) | 266 (8.6) | |
| Tis | 194 (4.7) | 0 (0) | 194 (6.3) | |
| Unknown | 42 (1.0) | 0 (0) | 42 (1.4) | |
| AJCC N stage | <.001 | |||
| Nx | 57 (1.4) | — | 57 (1.8) | |
| N0 | 3734 (90.8) | 1027 (100) | 2707 (87.7) | |
| N1 | 189 (4.6) | 0 (0) | 189 (6.1) | |
| N2 | 128 (3.1) | 0 (0) | 128 (4.1) | |
| N3 | — | — | — | |
| Unknown | — | — | — |
| Variable . | Total cohort, No. (%) . | Low riskb, No. (%) . | High riskb, No. (%) . | Pc . |
|---|---|---|---|---|
| Sex | .003 | |||
| Male | 2200 (53.5) | 590 (57.4) | 1610 (52.2) | |
| Female | 1914 (46.5) | 437 (42.6) | 1477 (47.8) | |
| Age at diagnosis, y | .003 | |||
| 66-70 | 612 (14.9) | 184 (17.9) | 428 (13.9) | |
| 71-75 | 920 (22.4) | 243 (23.7) | 677 (21.9) | |
| 76-80 | 956 (23.2) | 230 (22.4) | 726 (23.5) | |
| >80 | 1626 (39.5) | 370 (36.0) | 1256 (40.7) | |
| Race | .13 | |||
| Black | 128 (3.1) | 29 (2.8) | 99 (3.2) | |
| Hispanic | 56 (1.4) | 11 (1.1) | 45 (1.5) | |
| White | 3702 (90.0) | 943 (91.8) | 2759 (89.3) | |
| Other | 228 (5.5) | 44 (4.3) | 184 (6.0) | |
| Marital status | .80 | |||
| Single | 497 (12.1) | 121 (11.8) | 376 (12.2) | |
| Married | 2331 (56.6) | 591 (57.5) | 1740 (56.4) | |
| Unknown | 1286 (31.3) | 315 (30.7) | 971 (31.5) | |
| Census region | .01 | |||
| West | 1615 (39.3) | 364 (35.4) | 1251 (40.5) | |
| Midwest | 929 (22.6) | 264 (25.7) | 665 (21.5) | |
| South | 487 (11.8) | 125 (12.2) | 362 (11.7) | |
| Northeast | 1083 (26.3) | 274 (26.7) | 809 (26.2) | |
| Median income | .50 | |||
| Bottom quartile | 1095 (26.6) | 286 (27.8) | 809 (26.4) | |
| Second quartile | 1033 (25.1) | 263 (25.6) | 770 (24.9) | |
| Third quartile | 1003 (24.4) | 234 (22.8) | 769 (24.9) | |
| Fourth quartile | 983 (23.9) | 244 (23.8) | 739 (23.9) | |
| No. of comorbidities | .12 | |||
| 0 | 1817 (44.2) | 429 (41.7) | 1388 (45.0) | |
| 1 | 1023 (24.9) | 268 (26.1) | 755 (24.4) | |
| 2 | 597 (14.5) | 167 (16.3) | 430 (13.9) | |
| ≥3 | 677 (16.5) | 163 (15.9) | 514 (16.7) | |
| Year of diagnosis | .55 | |||
| 2004 | 458 (11.1) | 115 (11.2) | 343 (11.1) | |
| 2005 | 424 (10.3) | 115 (11.2) | 309 (10.0) | |
| 2006 | 405 (9.8) | 82 (8.0) | 323 (10.5) | |
| 2007 | 415 (10.1) | 107 (10.4) | 308 (10.0) | |
| 2008 | 455 (11.1) | 117 (11.4) | 338 (10.9) | |
| 2009 | 446 (10.8) | 119 (11.6) | 327 (10.6) | |
| 2010 | 382 (9.3) | 89 (8.7) | 293 (9.5) | |
| 2011 | 389 (9.5) | 100 (9.7) | 289 (9.4) | |
| 2012 | 364 (8.8) | 87 (8.5) | 277 (9.0) | |
| 2013 | 376 (9.1) | 96 (9.3) | 280 (9.1) | |
| Grade | <.001 | |||
| Low | 1318 (32.0) | 1027 (100) | 291 (9.4) | |
| High | 2556 (62.2) | 0 (0) | 2556 (82.8) | |
| Unknown | 240 (5.8) | 0 (0) | 240 (7.8) | |
| AJCC T stage | <.001 | |||
| Ta | 998 (24.3) | 680 (66.2) | 318 (10.3) | |
| T1 | 921 (22.4) | 347 (33.8) | 574 (18.6) | |
| T2 | 557 (13.5) | 0 (0) | 557 (18.0) | |
| T3 | 1136 (27.6) | 0 (0) | 1136 (36.8) | |
| T4 | 266 (6.5) | 0 (0) | 266 (8.6) | |
| Tis | 194 (4.7) | 0 (0) | 194 (6.3) | |
| Unknown | 42 (1.0) | 0 (0) | 42 (1.4) | |
| AJCC N stage | <.001 | |||
| Nx | 57 (1.4) | — | 57 (1.8) | |
| N0 | 3734 (90.8) | 1027 (100) | 2707 (87.7) | |
| N1 | 189 (4.6) | 0 (0) | 189 (6.1) | |
| N2 | 128 (3.1) | 0 (0) | 128 (4.1) | |
| N3 | — | — | — | |
| Unknown | — | — | — |
Cell counts less than 11 are designated with “—” and cannot be reported as mandated by Surveillance, Epidemiology and End Results–Medicare data use agreement for privacy concerns. AJCC = American Joint Committee on Cancer.
Patients were stratified into low- and high-risk disease groups based on criteria adapted from the European Association of Urology guidelines (6).
P values were calculated with a 2-sided χ2 test.
| Variable . | Total cohort, No. (%) . | Low riskb, No. (%) . | High riskb, No. (%) . | Pc . |
|---|---|---|---|---|
| Sex | .003 | |||
| Male | 2200 (53.5) | 590 (57.4) | 1610 (52.2) | |
| Female | 1914 (46.5) | 437 (42.6) | 1477 (47.8) | |
| Age at diagnosis, y | .003 | |||
| 66-70 | 612 (14.9) | 184 (17.9) | 428 (13.9) | |
| 71-75 | 920 (22.4) | 243 (23.7) | 677 (21.9) | |
| 76-80 | 956 (23.2) | 230 (22.4) | 726 (23.5) | |
| >80 | 1626 (39.5) | 370 (36.0) | 1256 (40.7) | |
| Race | .13 | |||
| Black | 128 (3.1) | 29 (2.8) | 99 (3.2) | |
| Hispanic | 56 (1.4) | 11 (1.1) | 45 (1.5) | |
| White | 3702 (90.0) | 943 (91.8) | 2759 (89.3) | |
| Other | 228 (5.5) | 44 (4.3) | 184 (6.0) | |
| Marital status | .80 | |||
| Single | 497 (12.1) | 121 (11.8) | 376 (12.2) | |
| Married | 2331 (56.6) | 591 (57.5) | 1740 (56.4) | |
| Unknown | 1286 (31.3) | 315 (30.7) | 971 (31.5) | |
| Census region | .01 | |||
| West | 1615 (39.3) | 364 (35.4) | 1251 (40.5) | |
| Midwest | 929 (22.6) | 264 (25.7) | 665 (21.5) | |
| South | 487 (11.8) | 125 (12.2) | 362 (11.7) | |
| Northeast | 1083 (26.3) | 274 (26.7) | 809 (26.2) | |
| Median income | .50 | |||
| Bottom quartile | 1095 (26.6) | 286 (27.8) | 809 (26.4) | |
| Second quartile | 1033 (25.1) | 263 (25.6) | 770 (24.9) | |
| Third quartile | 1003 (24.4) | 234 (22.8) | 769 (24.9) | |
| Fourth quartile | 983 (23.9) | 244 (23.8) | 739 (23.9) | |
| No. of comorbidities | .12 | |||
| 0 | 1817 (44.2) | 429 (41.7) | 1388 (45.0) | |
| 1 | 1023 (24.9) | 268 (26.1) | 755 (24.4) | |
| 2 | 597 (14.5) | 167 (16.3) | 430 (13.9) | |
| ≥3 | 677 (16.5) | 163 (15.9) | 514 (16.7) | |
| Year of diagnosis | .55 | |||
| 2004 | 458 (11.1) | 115 (11.2) | 343 (11.1) | |
| 2005 | 424 (10.3) | 115 (11.2) | 309 (10.0) | |
| 2006 | 405 (9.8) | 82 (8.0) | 323 (10.5) | |
| 2007 | 415 (10.1) | 107 (10.4) | 308 (10.0) | |
| 2008 | 455 (11.1) | 117 (11.4) | 338 (10.9) | |
| 2009 | 446 (10.8) | 119 (11.6) | 327 (10.6) | |
| 2010 | 382 (9.3) | 89 (8.7) | 293 (9.5) | |
| 2011 | 389 (9.5) | 100 (9.7) | 289 (9.4) | |
| 2012 | 364 (8.8) | 87 (8.5) | 277 (9.0) | |
| 2013 | 376 (9.1) | 96 (9.3) | 280 (9.1) | |
| Grade | <.001 | |||
| Low | 1318 (32.0) | 1027 (100) | 291 (9.4) | |
| High | 2556 (62.2) | 0 (0) | 2556 (82.8) | |
| Unknown | 240 (5.8) | 0 (0) | 240 (7.8) | |
| AJCC T stage | <.001 | |||
| Ta | 998 (24.3) | 680 (66.2) | 318 (10.3) | |
| T1 | 921 (22.4) | 347 (33.8) | 574 (18.6) | |
| T2 | 557 (13.5) | 0 (0) | 557 (18.0) | |
| T3 | 1136 (27.6) | 0 (0) | 1136 (36.8) | |
| T4 | 266 (6.5) | 0 (0) | 266 (8.6) | |
| Tis | 194 (4.7) | 0 (0) | 194 (6.3) | |
| Unknown | 42 (1.0) | 0 (0) | 42 (1.4) | |
| AJCC N stage | <.001 | |||
| Nx | 57 (1.4) | — | 57 (1.8) | |
| N0 | 3734 (90.8) | 1027 (100) | 2707 (87.7) | |
| N1 | 189 (4.6) | 0 (0) | 189 (6.1) | |
| N2 | 128 (3.1) | 0 (0) | 128 (4.1) | |
| N3 | — | — | — | |
| Unknown | — | — | — |
| Variable . | Total cohort, No. (%) . | Low riskb, No. (%) . | High riskb, No. (%) . | Pc . |
|---|---|---|---|---|
| Sex | .003 | |||
| Male | 2200 (53.5) | 590 (57.4) | 1610 (52.2) | |
| Female | 1914 (46.5) | 437 (42.6) | 1477 (47.8) | |
| Age at diagnosis, y | .003 | |||
| 66-70 | 612 (14.9) | 184 (17.9) | 428 (13.9) | |
| 71-75 | 920 (22.4) | 243 (23.7) | 677 (21.9) | |
| 76-80 | 956 (23.2) | 230 (22.4) | 726 (23.5) | |
| >80 | 1626 (39.5) | 370 (36.0) | 1256 (40.7) | |
| Race | .13 | |||
| Black | 128 (3.1) | 29 (2.8) | 99 (3.2) | |
| Hispanic | 56 (1.4) | 11 (1.1) | 45 (1.5) | |
| White | 3702 (90.0) | 943 (91.8) | 2759 (89.3) | |
| Other | 228 (5.5) | 44 (4.3) | 184 (6.0) | |
| Marital status | .80 | |||
| Single | 497 (12.1) | 121 (11.8) | 376 (12.2) | |
| Married | 2331 (56.6) | 591 (57.5) | 1740 (56.4) | |
| Unknown | 1286 (31.3) | 315 (30.7) | 971 (31.5) | |
| Census region | .01 | |||
| West | 1615 (39.3) | 364 (35.4) | 1251 (40.5) | |
| Midwest | 929 (22.6) | 264 (25.7) | 665 (21.5) | |
| South | 487 (11.8) | 125 (12.2) | 362 (11.7) | |
| Northeast | 1083 (26.3) | 274 (26.7) | 809 (26.2) | |
| Median income | .50 | |||
| Bottom quartile | 1095 (26.6) | 286 (27.8) | 809 (26.4) | |
| Second quartile | 1033 (25.1) | 263 (25.6) | 770 (24.9) | |
| Third quartile | 1003 (24.4) | 234 (22.8) | 769 (24.9) | |
| Fourth quartile | 983 (23.9) | 244 (23.8) | 739 (23.9) | |
| No. of comorbidities | .12 | |||
| 0 | 1817 (44.2) | 429 (41.7) | 1388 (45.0) | |
| 1 | 1023 (24.9) | 268 (26.1) | 755 (24.4) | |
| 2 | 597 (14.5) | 167 (16.3) | 430 (13.9) | |
| ≥3 | 677 (16.5) | 163 (15.9) | 514 (16.7) | |
| Year of diagnosis | .55 | |||
| 2004 | 458 (11.1) | 115 (11.2) | 343 (11.1) | |
| 2005 | 424 (10.3) | 115 (11.2) | 309 (10.0) | |
| 2006 | 405 (9.8) | 82 (8.0) | 323 (10.5) | |
| 2007 | 415 (10.1) | 107 (10.4) | 308 (10.0) | |
| 2008 | 455 (11.1) | 117 (11.4) | 338 (10.9) | |
| 2009 | 446 (10.8) | 119 (11.6) | 327 (10.6) | |
| 2010 | 382 (9.3) | 89 (8.7) | 293 (9.5) | |
| 2011 | 389 (9.5) | 100 (9.7) | 289 (9.4) | |
| 2012 | 364 (8.8) | 87 (8.5) | 277 (9.0) | |
| 2013 | 376 (9.1) | 96 (9.3) | 280 (9.1) | |
| Grade | <.001 | |||
| Low | 1318 (32.0) | 1027 (100) | 291 (9.4) | |
| High | 2556 (62.2) | 0 (0) | 2556 (82.8) | |
| Unknown | 240 (5.8) | 0 (0) | 240 (7.8) | |
| AJCC T stage | <.001 | |||
| Ta | 998 (24.3) | 680 (66.2) | 318 (10.3) | |
| T1 | 921 (22.4) | 347 (33.8) | 574 (18.6) | |
| T2 | 557 (13.5) | 0 (0) | 557 (18.0) | |
| T3 | 1136 (27.6) | 0 (0) | 1136 (36.8) | |
| T4 | 266 (6.5) | 0 (0) | 266 (8.6) | |
| Tis | 194 (4.7) | 0 (0) | 194 (6.3) | |
| Unknown | 42 (1.0) | 0 (0) | 42 (1.4) | |
| AJCC N stage | <.001 | |||
| Nx | 57 (1.4) | — | 57 (1.8) | |
| N0 | 3734 (90.8) | 1027 (100) | 2707 (87.7) | |
| N1 | 189 (4.6) | 0 (0) | 189 (6.1) | |
| N2 | 128 (3.1) | 0 (0) | 128 (4.1) | |
| N3 | — | — | — | |
| Unknown | — | — | — |
Cell counts less than 11 are designated with “—” and cannot be reported as mandated by Surveillance, Epidemiology and End Results–Medicare data use agreement for privacy concerns. AJCC = American Joint Committee on Cancer.
Patients were stratified into low- and high-risk disease groups based on criteria adapted from the European Association of Urology guidelines (6).
P values were calculated with a 2-sided χ2 test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
